Improvement of fibrinolytical function in chronic rheumatic atrial fibrillation after anticoagulation;Mejoría de la función fibrinolítica tras el tratamiento anticoagulante en la fibrilación auricular reumática crónica

Revista Espanola de Cardiologia

Volumn 52, Issue 1, 1999, Pages 25-30

  Ortuño, Francisco Marín ^a   Schilling, Vanessa Roldán ^a   Vera, Pascual Marco ^a   Martínez, Juan Gabriel Martínez ^a   Noguera, Antonio Toral ^a   De Burgos Rico, Fernando García ^a   Sendra, Ramiro Calatayud ^a   Garri, Francisco Sogorb ^a  

^a NONE

Author keywords

Anticoagulants; Atrial fibrillation; Fibrinolysis

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; BLOOD; CHRONIC DISEASE; DRUG EFFECT; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MIDDLE AGED; MITRAL VALVE STENOSIS; NONPARAMETRIC TEST; RHEUMATIC HEART DISEASE; TIME;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; ECHOCARDIOGRAPHY; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE STENOSIS; RHEUMATIC HEART DISEASE; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 0032604978     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(99)74861-x     Document Type: Article

References (20)

1. Dunn M, Alexander J, De Silva R, Hildner F. Antithrombotic therapy in atrial fibrillation. Chest 1989; 95 (Supl): 118-127.
2. Yamamoto K, Ikeda U, Seino Y, Mito H, Fujikawa H, Sekiguchi H et al. Coagulation activity is increased in the left atrium of patients with mitral stenosis. J Am Coll Cardiol 1995; 25: 107-112.
3. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973-977.
4. Jafri SM, Caceres L, Rosman HS, Ozawa T, Mammen E. Lesch M et al. Activation of the coagulation system in women with mitral stenosis and sinus rhythm. Am J Cardiol 1992; 70: 1.217-1.219.
5. Hirsh J, Fustei V. Guide to anticoagulant therapy. Part two: oral anticoagulants. Circulation 1994; 89: 1.469-1.480.
6. Koefoed BG, Gulloøv AL, Petersen P. Prevention of thromboembolic events in atrial fibrillation. Thromb Haemost 1997; 77: 377-381.
7. Lip GYH. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995; 346: 1.313-1.314.
8. Kumagai K, Fukunami M, Ohmori M, Kitabatake A, Kamada T, Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990; 16: 377-380.
9. Lip GYH, Lowe GOD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995; 73: 527-533.
10. Yamamoto K, Ikeda U, Fukazawa H, Shimada K. Effects of aspirin on the status of thrombin generation in atrial fibrillation. Am J Cardiol 1996; 77: 528-530.
11. Yasaka M, Miyatake K, Mitani M, Beppu S, Nagata S, Yamaguchi T et al. Intracardiac mobile thrombus and D-dimer fragment in patients will mitral stenosis. Br Heart J 1991; 66: 22-25.
12. Kistler JP, Singer DE, Millenson MM, Bauer KA, Gress DR. Barzegar S et al. Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. Stroke 1993; 24: 1.360-1.365.
13. Wiman B. Plasminogen activator inhibitor I (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995; 74: 71-76.
14. Peverill RE, Harris G, Gelman J, Gan TE, Harper RW, Smolich JJ. Effect of warfarin on regional left atrial coagulation activity in mitral stenosis. Am J Cardiol 1997; 79: 339-343.
15. Lip GYH, Lip PL. Zarifis J, Watson RDS. Bareford D, Lowe GDO et al. Fibrin D-dimer and b-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Circulation 1996; 94: 425-431.
16. Lip GYH, Low G. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J 1996; 131: 724-730.
17. Mitusch R, Siemens HJ, Garbe M, Wagner T, Sheikhadeh A, Diederich KW. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost 1996; 75: 219-223.
18. Lindgren A, Lindoff C, Norrving B, Astedt B. Johansson BB. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 1996; 27: 1.066-1.071.
19. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943.
20. Juhan-Vague I, Pyke S, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2.057-2.063.